Latest Annual General Meeting News

Anatara Lifesciences has completed the final tranche of its placement, issuing over 66 million shares and granting options to its lead manager, marking a key step in its capital raising strategy.

Maggie Beer Holdings reveals strategic progress in its 2025 AGM, focusing on operational simplification, financial stability, and targeted growth for its iconic brands.

Hancock & Gore is rebranding as Schoolblazer Limited following its acquisition of Trutex, consolidating its global school uniform operations and targeting over $200 million in revenue by FY27.

Impact Minerals Limited’s recent attempt to issue options to placement participants was rejected by shareholders at the AGM, halting a key incentive plan while the company continues to focus on its high-purity alumina projects.

Invictus Energy updates progress on its AMOG joint venture with Al Mansour Holdings, revealing ongoing negotiations for a significant Qatari ownership stake and deferral of a key placement settlement.

Harvey Norman Holdings detailed its expansive international growth and omni-channel strategy at its 2025 AGM, highlighting new flagship stores and AI-driven retail innovations across eight countries.

Aura Energy’s 2025 AGM highlights strong uranium market fundamentals and strategic progress on its Tiris Project, despite some engineering delays. The company also strengthens its board and deepens ties in Mauritania as it prepares for production.

Jameson Resources Limited has updated its Employee Share Option Plan, approved at the 2025 AGM, aiming to better incentivize and retain key personnel while aligning employee interests with shareholders.

Pure Foods Tasmania has acquired premium ice cream brand Elato, integrating it with its Cashew Creamery to form a new Ice Cream Division led by Elato’s founder. This move broadens PFT’s product range and leverages existing manufacturing capabilities.

Mesoblast Limited forecasts a significant jump in quarterly revenue, driven by strong sales of its FDA-approved cell therapy Ryoncil. The company’s latest update highlights robust growth and ongoing expansion in inflammatory disease treatments.

Acrux Ltd reported a remarkable surge in licensing revenue from its topical generics portfolio alongside a strategic pivot towards innovative drug delivery R&D at its 2025 Annual General Meeting.

A former director of Emu NL has lodged a formal application with the Takeovers Panel, contesting the legitimacy of a recent $1.4 million institutional placement and alleging undisclosed attempts to influence board control.